MC-MMAF
|
|
|
- CAS-Nr.
- 863971-19-1
- Englisch Name:
- MC-MMAF
- Synonyma:
- McMMAF;Mc-MMAF;L4-MMAF;SGD 1269;Mafodotin;SGD-1269(MCMMAF);Maleimidocaproyl-MMAF;MaleiMidocaproyl MonoMethylauristatin F;2-Piperidinecarboxylicacid,methylester,(2R)-,hydrochloride(1:3);N-[6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-L-phenylalanine
- CBNumber:
- CB32667279
- Summenformel:
- C49H76N6O11
- Molgewicht:
- 925.16
- MOL-Datei:
- 863971-19-1.mol
|
MC-MMAF Eigenschaften
- Siedepunkt:
- 1052.0±65.0 °C(Predicted)
- Dichte
- 1.167±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- Löslichkeit
- DMSO : ≥ 100 mg/mL (108.09 mM)
- pka
- 3.56±0.10(Predicted)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H300 |
Lebensgefahr bei Verschlucken. |
Akute Toxizität oral |
Kategorie 2 |
Achtung |
![GHS hazard pictograms]() src="/GHS06.jpg" width="20" height="20" /> |
P264, P270, P301+P310, P321, P330,P405, P501 |
| H310 |
Lebensgefahr bei Hautkontakt. |
Acute toxicity,dermal |
Category 1, 2 |
Achtung |
![GHS hazard pictograms]() src="/GHS06.jpg" width="20" height="20" /> |
P262, P264, P270, P280, P302+P350,P310, P322, P361, P363, P405, P501 |
| H330 |
Lebensgefahr bei Einatmen. |
Akute Toxizität inhalativ |
Kategorie 1 |
Achtung |
![GHS hazard pictograms]() src="/GHS06.jpg" width="20" height="20" /> |
P260, P271, P284, P304+P340, P310,P320, P403+P233, P405, P501 |
|
| Sicherheit |
| P260 |
Dampf/Aerosol/Nebel nicht einatmen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P284 |
Atemschutz tragen. |
| P301+P310 |
BEI VERSCHLUCKEN: Sofort GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
| P302+P350 |
BEI KONTAKT MIT DER HAUT: Behutsam mit viel Wasser und Seife waschen. |
|
MC-MMAF Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
MC-MMAF is an antibody that binds to the epidermal growth factor receptor (EGFR) on tumor cells and inhibits the proliferation of tumor cells by blocking the binding of epidermal growth factor. MC-MMAF has been shown to be an effective treatment for a variety of cancers, including breast cancer, lung cancer, head and neck cancer, and colorectal cancer. It is also being studied as a potential treatment for autoimmune diseases such as rheumatoid arthritis and psoriasis. MC-MMAF has been shown to improve prognosis in patients with glomerular filtration rate (GFR) less than 30 mL/min per 1.73 m2.
Verwenden
Mafodotin is an anticancer immunoconjugate for the diagnosis and treatment of cancer or B Cell proliferative diseases.
Biologische Aktivität
McMMAF is a protective group (maleimidocaproyl)-conjugated MMAF, which is a potent tubulin polymerization inhibitor. McMMAF can be used as a drug-linker for?antibody-drug conjugates (ADC). McMMAF ADCs are uncleavable, and must be internalized and degraded within a cell, releasing cysteine-McMMAF as the active drug.
in vivo
Dose response of anti-tumor activity, characterized in the Bjab-Luc xenograft model, yielded an ED50 of ～1 mg/kg for MC-MMAF. MCC-DM1 was about 2-fold less potent compared to MC-MMAF in this model. Conjugation with DM1 or MMAF appeared to have minimal impact on the PK of anti-CD22 when the PK of naked anti-CD22 was compared with the total antibody PK profile in all three species. Pharmacokinetic parameters of both total antibody and ADCs were generally dose proportional at the dose range studied. Free DM1 in plasma increased with dose, while free MMAF was not detected[2].
MC-MMAF Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
MC-MMAF Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 107)Lieferanten
- Mafodotin
- MaleiMidocaproyl MonoMethylauristatin F
- McMMAF
- Mc-MMAF
- SGD 1269
- (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-methylhexanamido)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoic aci
- (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-methylhexanamido)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoic acid
- SGD-1269(MCMMAF)
- L-Phenylalanine, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-
- (2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropan
- N-[6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-L-phenylalanine
- 2-Piperidinecarboxylicacid,methylester,(2R)-,hydrochloride(1:3)
- N-[6-(2,5-Dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-L-phenylalanine
- L4-MMAF
- Maleimidocaproyl-MMAF
- 863971-19-1
- C49H76N6O11
- Amino Acids & Derivatives, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
- ADCs
